HIV-associated lipoatrophy: What are the kinder, gender agents?

Clinical Infectious Diseases

Volumn 42, Issue 2, 2006, Pages 281-282

  Dubé, Michael P ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b WISHARD MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

BODY FAT; CD4 LYMPHOCYTE COUNT; DUAL ENERGY X RAY ABSORPTIOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; NOTE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INFECTION;

ANTI-HIV AGENTS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS;

EID: 30144440513     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/498525     Document Type: Note

References (8)

1. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62.
2. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
3. Dubé MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19:1807-18.
4. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17:971-9.
5. Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005; 39:395-400.
6. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36:1011-9.
7. Jemsek JG, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis 2005; 42:273-80 (in this issue).
8. Dubé MP, Qian D, Edmondson-Melançon H, et al. Prospective, 48-week, intensive metabolic study of amprenavir-based therapy. Clin Infect Dis 2002; 35:475-81.